PRTG250117C2500
- 0.15
- 0.000.00%
Portage Biotech Newsroom
Express News | Portage Biotech Shares Are Trading Higher After the Company Announced the Spinoff of Its Subsidiary Cyncado Therapeutics
Portage Biotech Re-Launches Subsidiary as Cyncado Therapeutics With New CEO
Portage: Cyncado to Focus on Advancing Clinical Development of A2a and A2b Receptor Antagonists to Achieve Proof-of-Concept Data for Its Therapeutics >PRTG
Portage Biotech: Peter Molloy Appointed to Lead New Company >PRTG
Portage Biotech: Adenosine Subsidiary to Become an Independently Managed Company >PRTG
Top Premarket Decliners
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Portage Biotech PRTG LOI; Reviva RVPH Offering
Trending Stocks Today | Nukkleus Surges 871.22%
What's Going On With Portage Biotech Shares Tuesday?
Crude Oil Down Over 1%; US Industrial Production Declines In November
Dow Dips Over 200 Points; US Retail Sales Top Estimates
Express News | Portage Biotech Shares Halted For Volatility
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
Portage Biotech Shares Soar Over 212% in Premarket Activity After Announcing Entering Letter of Intent With Immunova
Top Premarket Gainers
Express News | Market-Moving News for December 17th
Portage Biotech Announces Letter Of Intent With Immunova For An Option To Acquire IOx Therapeutics, Ltd >PRTG
Press Release: Portage Biotech Announces Letter of Intent With Immunova for an Option to Acquire IOx Therapeutics, Ltd